Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.73 |
| ▸ | CNR1 | P21554 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14911238 | 0.94 | CNR2 (0.73) | CNR2CNR1 | |
| SCHEMBL14911384 | 0.89 | CNR2 (0.72) | CNR2CNR1KDM4EALDH1A1LMNA | |
| SCHEMBL14911363 | 0.89 | CNR2 (0.79) | CNR2CNR1KDM4EALDH1A1LMNA | |
| SCHEMBL14911501 | 0.89 | CNR2 (0.80) | CNR2CNR1 | |
| SCHEMBL14911354 | 0.88 | CNR2 (0.77) | CNR2CNR1 | |
| SCHEMBL14911666 | 0.87 | CNR2 (0.70) | CNR2CNR1KDM4EALDH1A1LMNA | |
| SCHEMBL14911361 | 0.87 | CNR2 (0.76) | CNR2CNR1KDM4EALDH1A1LMNA | |
| SCHEMBL14911237 | 0.87 | CNR2 (0.76) | CNR2CNR1KDM4EALDH1A1LMNA | |
| SCHEMBL14911743 | 0.86 | CNR2 (0.70) | CNR2CNR1KDM4EALDH1A1LMNA | |
| SCHEMBL14911745 | 0.86 | CNR2 (0.70) | CNR2CNR1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776442-B1 | [1, 2, 3]TRIAZOLO [4, 5 -D]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | claimed |
| US-8741906-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | claimed |
| US-20130116236-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | claimed |
| EP-2776442-B1 | [1, 2, 3]TRIAZOLO [4, 5 -D]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | disclosed |
| EP-2776442-B1 | [1, 2, 3]TRIAZOLO [4, 5 -D]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-9056866-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056866-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056866-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20140288046-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288046-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288046-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8741906-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741906-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741906-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| WO-2013068306-A1 | [1, 2, 3] TRIAZOLO [4, 5 -D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-16 | — | — | WO | disclosed |
| US-20130116236-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116236-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116236-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116236-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TBXA2R, TYMP | CNR2 129/4885CNR1 98/4885KDM4E 2849/4885 |
| US-20140288046-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TBXA2R, TYMP | CNR2 129/4885CNR1 98/4885KDM4E 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.